PHASE-II EVALUATION OF METHYL-GAG IN PATIENTS WITH REFRACTORY METASTATIC BREAST-CANCER

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (5-6) , 465-467
Abstract
Patients (29) with metastatic breast cancer were treated with methyl-GAG [methylglyoxalbis-(guanylhydrazone)] at an initial starting dose of 500 mg/m2 i.v. weekly and then escalated by 50 mg/m2 per wk to tolerance. There were 2 partial responders among the 26 evaluable patients. Gastrointestinal and cutaneous reactions were the limiting toxic effects of methyl-GAG. Myelosuppression was mild and infrequent.